Avelumab

證據等級: L5

預測適應症: 10 個

One-Sentence Summary

Avelumab is an anti-PD-L1 monoclonal antibody checkpoint inhibitor, approved internationally for Merkel cell carcinoma and urothelial carcinoma maintenance therapy. The TxGNN model predicts it may be effective for Human Herpesvirus 8 (HHV-8)-Related Tumors (including Kaposi sarcoma and primary effusion lymphoma), with 0 clinical trials and 0 publications in the current evidence pack supporting this specific direction — this remains a model-generated hypothesis only.

Quick Overview

Item	Content
Original Indication	Merkel cell carcinoma; urothelial carcinoma (first-line maintenance) (Note: original_indications field is empty in source data; based on known international approvals)
Predicted New Indication	Human Herpesvirus 8-Related Tumor
TxGNN Prediction Score	99.97%
Evidence Level	L5
Singapore Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why Is This Prediction Reasonable?

Avelumab is a fully human IgG1 anti-PD-L1 monoclonal antibody. By blocking PD-L1 on tumour cells, it prevents the PD-1/PD-L1 interaction that suppresses cytotoxic T cells, thereby restoring the immune system's ability to recognize and destroy cancer cells. Notably, as an IgG1 antibody, Avelumab also retains the ability to induce antibody-dependent cellular cytotoxicity (ADCC), which distinguishes it mechanistically from other checkpoint inhibitors.

HHV-8 causes oncogenesis primarily through viral proteins that upregulate cellular PD-L1 expression — particularly in Kaposi sarcoma (KS) and primary effusion lymphoma (PEL). This PD-L1 upregulation is a key mechanism by which HHV-8-infected tumour cells evade immune surveillance. On this basis, blocking PD-L1 with Avelumab is mechanistically plausible: restoring T-cell cytotoxicity against virus-transformed cells is conceptually sound.

The analogy to Merkel cell carcinoma (MCC) — Avelumab's primary approved indication — provides additional support. MCC is a virus-associated (Merkel cell polyomavirus) neuroendocrine skin tumour that also relies on PD-L1-mediated immune evasion, and checkpoint inhibition has proven highly effective. HHV-8-associated malignancies share this virus-driven, PD-L1-dependent immune escape biology, making the TxGNN prediction biologically coherent. However, it should be noted that the MOA data field is listed as a data gap in the source pack, and the connection currently rests on known pharmacology rather than data formally submitted to this pipeline.

Clinical Trial Evidence

Currently no related clinical trials registered for Avelumab in human herpesvirus 8-related tumor.

Note: External literature outside this evidence pack contains preliminary case reports on checkpoint inhibitors (including PD-1/PD-L1 blockade) in Kaposi sarcoma. A targeted PubMed search is recommended to supplement this gap before advancing to any decision stage.

Literature Evidence

Currently no related literature available within this evidence pack for Avelumab in human herpesvirus 8-related tumor.

Singapore Market Information

Avelumab has no Singapore Health Sciences Authority (HSA) registrations. The drug is not marketed in Singapore as of the data cutoff (2026-04-05).

Authorization Number	Product Name	Dosage Form	Approved Indication
—	—	—	No registrations found

Cytotoxicity

Avelumab is an antineoplastic agent (immunotherapy class). The following applies:

Item	Content
Cytotoxicity Classification	Immunotherapy — Checkpoint inhibitor (anti-PD-L1 IgG1 monoclonal antibody); not a conventional cytotoxic agent
Myelosuppression Risk	Low (direct myelosuppression is not a primary toxicity; immune-mediated haematological events such as immune thrombocytopenia are possible but uncommon)
Emetogenicity Classification	Minimal to low
Monitoring Items	CBC with differential; liver function tests (ALT, AST, bilirubin); thyroid function (TSH, free T4); renal function; blood glucose; adrenal function if clinically indicated; infusion reaction monitoring during administration
Handling Protection	Standard biologic/monoclonal antibody handling protocols apply; does not require cytotoxic chemotherapy-level containment procedures, but facility-specific biosafety guidelines for IV administration should be followed

Safety Considerations

Detailed TFDA package insert warnings and contraindications were not available in this evidence pack (Data Gap DG001). Known class-level safety considerations for PD-L1 checkpoint inhibitors include:

Immune-Related Adverse Events (irAEs): Pneumonitis, colitis, hepatitis, endocrinopathies (thyroiditis, adrenal insufficiency, hypophysitis), nephritis, and dermatitis — any of which can be severe or life-threatening
Infusion-Related Reactions: Premedication with antihistamine and paracetamol is recommended prior to the first four infusions
Special Populations: Use in patients with active autoimmune disease, immunodeficiency, or those on systemic immunosuppressants requires individual risk-benefit assessment

Please refer to the full Bavencio® (Avelumab) international prescribing information for complete warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model assigns a high prediction score (99.97%) driven by a mechanistically coherent hypothesis — HHV-8-driven PD-L1 upregulation as a target for Avelumab — but no clinical trials or peer-reviewed literature have been retrieved in this evidence pack to support advancement. This is a pure model-generated signal (Evidence Level L5) requiring hypothesis validation before any clinical or regulatory pathway can be considered.

To proceed, the following is needed:

Targeted PubMed search: Search for case reports, retrospective series, or proof-of-concept studies on PD-1/PD-L1 checkpoint inhibitors in Kaposi sarcoma and primary effusion lymphoma (these likely exist outside the current pipeline's capture)
MOA data gap resolution (DG002): Formally retrieve Avelumab's mechanism of action from DrugBank API to strengthen the mechanistic narrative
Safety data gap resolution (DG001): Obtain and parse the TFDA or equivalent package insert PDF to complete the S1 safety screen
Singapore regulatory pathway assessment: Given zero HSA registrations, an independent import/compassionate use or clinical trial IND pathway would be required for any local use
PD-L1 expression evidence in HHV-8 tumours: Identify published biomarker studies confirming PD-L1 expression in Kaposi sarcoma or PEL tumour tissue to strengthen the translational rationale before escalating to Research Question status
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.